JP5525814B2 - ２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液の調製方法 - Google Patents

２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液の調製方法 Download PDF

Info

Publication number
JP5525814B2
JP5525814B2 JP2009511321A JP2009511321A JP5525814B2 JP 5525814 B2 JP5525814 B2 JP 5525814B2 JP 2009511321 A JP2009511321 A JP 2009511321A JP 2009511321 A JP2009511321 A JP 2009511321A JP 5525814 B2 JP5525814 B2 JP 5525814B2
Authority
JP
Japan
Prior art keywords
ginsenoside
cyclodextrin
raw material
water
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009511321A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009537572A (ja
JP2009537572A5 (https=
Inventor
富力
劉紅
魯明明
魯岐
趙誠太
崔万哲
Original Assignee
大▲連▼富生天然▲薬▼物▲開▼▲発▼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大▲連▼富生天然▲薬▼物▲開▼▲発▼有限公司 filed Critical 大▲連▼富生天然▲薬▼物▲開▼▲発▼有限公司
Publication of JP2009537572A publication Critical patent/JP2009537572A/ja
Publication of JP2009537572A5 publication Critical patent/JP2009537572A5/ja
Application granted granted Critical
Publication of JP5525814B2 publication Critical patent/JP5525814B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2009511321A 2006-05-22 2007-05-18 ２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液の調製方法 Expired - Fee Related JP5525814B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2006100466172A CN1883492B (zh) 2006-05-22 2006-05-22 20(R)-人参皂苷Rg3药用组合物水溶液及制备方法
CN200610046617.2 2006-05-22
PCT/CN2007/001635 WO2007134534A1 (fr) 2006-05-22 2007-05-18 Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant

Publications (3)

Publication Number Publication Date
JP2009537572A JP2009537572A (ja) 2009-10-29
JP2009537572A5 JP2009537572A5 (https=) 2013-02-14
JP5525814B2 true JP5525814B2 (ja) 2014-06-18

Family

ID=37581875

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511321A Expired - Fee Related JP5525814B2 (ja) 2006-05-22 2007-05-18 ２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液の調製方法

Country Status (10)

Country Link
US (2) US8487090B2 (https=)
EP (1) EP2025339B1 (https=)
JP (1) JP5525814B2 (https=)
KR (2) KR20090014300A (https=)
CN (1) CN1883492B (https=)
AU (1) AU2007252183B2 (https=)
CA (1) CA2653085C (https=)
ES (1) ES2477873T3 (https=)
RU (1) RU2432164C2 (https=)
WO (1) WO2007134534A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512404A (ja) * 2008-02-19 2011-04-21 ユニジェン インク． 運動能力、疲労回復および抗酸化活性の改善のための、Ｐａｎａｘ（トチバニンジン属）の種の植物の葉の抽出物または処理されたＰａｎａｘ種植物葉抽出物または双方の混合物を含む組成物
CN101530389B (zh) * 2008-03-11 2012-02-15 沈阳市万嘉生物技术研究所 人参皂苷Rg3磷脂复合物及其制备方法
CN102091114B (zh) * 2009-12-15 2014-11-26 河北以岭医药研究院有限公司 一种中药冻干注射剂及其制备方法
KR100992800B1 (ko) * 2010-05-14 2010-11-08 주식회사 지씨에이치앤피 미량의 진세노사이드 성분이 증가된 신규한 가공인삼 또는 가공인삼추출물의 제조방법
CN103845280B (zh) * 2012-11-30 2017-04-12 富力 一种20(R)‑人参皂苷Rg3外用制剂、制法与用途
CN103845348B (zh) * 2012-11-30 2016-07-13 富力 20(R)-人参皂苷Rg3在制备痛经药物中的应用
KR101316095B1 (ko) * 2013-01-30 2013-10-11 경희대학교 산학협력단 진세노사이드 Ｒｂ１ 및 Ｒｇ３，Ｃｏｍｐｏｕｎｄ Ｋ，또는 인삼유래 사포닌 추출물을 유효성분으로 함유하는 신경병증성 통증 예방 및 치료용 조성물
KR102021463B1 (ko) * 2013-04-24 2019-09-16 (주)아모레퍼시픽 진세노사이드 Rg3를 함유하는 피부 외용제 조성물
KR101595426B1 (ko) 2013-08-30 2016-02-18 (주)녹십자웰빙 진세노사이드 성분이 증가된 가공인삼분말 또는 가공인삼추출물을 함유하는 암 관련 피로의 예방 및 치료용 조성물
CN104643058A (zh) * 2013-11-21 2015-05-27 富力 20(R)-人参皂苷Rg3在制备改善或/和治疗肝硬化疾病的药物中的应用
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物
CN105012315A (zh) * 2014-04-24 2015-11-04 上海中医药大学 20(r)-原人参二醇的医药用途
CN105777838A (zh) * 2014-12-17 2016-07-20 富力 20(R)-人参皂苷Rg3衍生物、制备方法及其应用
CN105982906A (zh) * 2015-02-11 2016-10-05 富力 20(R)-人参皂苷Rg3在制备缓解或/和治疗类风湿病症的药物或保健品中的应用及药物
KR101772759B1 (ko) 2015-09-25 2017-08-30 순천향대학교 산학협력단 안정화된 무정형의 20(R)-진세노사이드 Rg3, 이의 제조방법 및 이를 함유하는 약제학적 제제
CN105878206A (zh) * 2016-03-31 2016-08-24 北京万全德众医药生物技术有限公司 一种人参皂苷Rg3的软胶囊及其制备方法
KR20180000379A (ko) * 2016-06-22 2018-01-03 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 유효성분으로 포함하는 면역증강용 조성물
CN108310106A (zh) * 2018-03-30 2018-07-24 吉林省恒实传食品科技发展有限公司 一种补肾填髓、健脑益智、辅助改善记忆的中药组合物及其应用
KR20200112012A (ko) * 2019-03-20 2020-10-05 순천대학교 산학협력단 (R)-진세노사이드 Rg3를 유효성분으로 포함하는 피부상처 치유 또는 피부재생 촉진용 조성물
CN111686104A (zh) * 2020-07-01 2020-09-22 香港浸会大学深圳研究院 小白菊内酯、木犀草素、金圣草素和人参皂苷Rg3的新用途
CN112245443A (zh) * 2020-08-25 2021-01-22 富力 人参皂苷Rg3与Rg5的组合物及其抗肿瘤等药用
CN116077442A (zh) * 2023-01-06 2023-05-09 吉林大学 一种含有人参皂苷Rg3的纳米颗粒及其制备方法和应用
KR102756809B1 (ko) * 2023-10-13 2025-01-22 표재성 난용성 진세노사이드의 수용해도를 높인 조성물, 이를 이용한 화장품조성물 및 건강기능식품

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1186015C (zh) 2001-01-18 2005-01-26 天津实验动物中心 用于冠心病心绞痛的中药复方口腔贴膜
CN1167734C (zh) * 2001-07-02 2004-09-22 董英杰 人参皂甙Rg3羟丙基-β-环糊精包合物及制剂和制备方法
CN1526405A (zh) * 2003-01-06 2004-09-08 山东绿叶天然药物研究开发有限公司 抗肿瘤的人参皂苷Rg3注射剂及其制备方法
CN1569012A (zh) * 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20(R)－人参皂苷－Rg3在制备治疗或预防高血压的药物中的应用
CN1569011A (zh) 2003-07-24 2005-01-26 山东绿叶天然药物研究开发有限公司 20（R）－人参皂苷－Rg3在制备治疗或预防心脑血管疾病的药物中的应用
WO2005034963A1 (en) * 2003-10-15 2005-04-21 Panagin Pharmaceuticals Inc. USE OF GINSENOSIDES Rh2 & Rg3, AND AGLYCON GINSENOSIDES FOR THE PREVENTION OF CANCER

Also Published As

Publication number Publication date
EP2025339A1 (en) 2009-02-18
RU2008150468A (ru) 2010-06-27
JP2009537572A (ja) 2009-10-29
AU2007252183B2 (en) 2013-07-11
KR20120054664A (ko) 2012-05-30
US9333215B2 (en) 2016-05-10
CA2653085C (en) 2016-01-19
US20130345156A1 (en) 2013-12-26
CN1883492B (zh) 2010-07-28
CN1883492A (zh) 2006-12-27
ES2477873T3 (es) 2014-07-18
KR101221680B1 (ko) 2013-01-11
KR20090014300A (ko) 2009-02-09
AU2007252183A1 (en) 2007-11-29
US20120149656A1 (en) 2012-06-14
US8487090B2 (en) 2013-07-16
WO2007134534A1 (fr) 2007-11-29
RU2432164C2 (ru) 2011-10-27
EP2025339A4 (en) 2013-01-16
CA2653085A1 (en) 2007-11-29
EP2025339B1 (en) 2014-04-16

Similar Documents

Publication Publication Date Title
JP5525814B2 (ja) ２０（Ｒ）−人参サポニン（ジンセノサイド）Ｒｇ３薬用組成物水溶液の調製方法
Qiao et al. Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan
Guan et al. N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy
US10898577B2 (en) Conjugate of ginsenoside compound K and glycol chitosan and an anti-tumor use thereof
Hong et al. Annonaceous acetogenins (ACGs) nanosuspensions based on a self-assembly stabilizer and the significantly improved anti-tumor efficacy
JP7466822B2 (ja) 亜鉛－γ－ＰＧＡ組成物およびがんを処置するための方法
CN109875964B (zh) 一种阿霉素无载体纳米药物的制备及其应用
Ren et al. Preparation, characterization and controlled-release property of CS crosslinked MWCNT based on Hericium erinaceus polysaccharides
CN119679961A (zh) 一种治疗溃疡性结肠炎的蛋白纳米粒及其制备方法和应用
Qian et al. Evaluation of cisplatin-hydrogel for improving localized antitumor efficacy in gastric cancer
CN107049944B (zh) 一种可实现索拉非尼和姜黄素同时给药的聚合物胶束及其制备方法
CN101433535A (zh) 一种用于肿瘤化学治疗中的新型增敏和增效物质
CN105012234B (zh) 一种二甲氧基姜黄素聚合物胶束及其制备方法与医药用途
CN102159190A (zh) 化疗剂的口服制剂
EP2934593B1 (en) Cabazitaxel composition
CN116515011B (zh) 一种基于透明质酸的两亲性接枝共聚物及其制备方法和应用
CN108524951A (zh) 一种具有肝肿瘤靶向作用的索拉菲尼纳米制剂
RU2485956C2 (ru) Новая композиция для лечения побочных эффектов противораковой терапии
CN113384541B (zh) 一种用于防治早期神经退行性疾病的鼻腔纳米自噬诱导剂及其制备方法
CN109419773B (zh) 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用
CN105616384A (zh) 一种包载紫杉醇的tpgs-还原性白蛋白纳米粒制剂及制备方法
CN111542328A (zh) 用于治疗癌症的包含α-聚谷氨酸-锌的组合物
CN115844874A (zh) 一种药物组合物及其在制备治疗肝纤维化药物中的应用
WO2008061429A1 (fr) Procédé d'utilisation de triacontanol visant à préparer des médicaments destinés à traiter des cancers
CN108272745B (zh) 一种二甲双胍/熊果酸纳米口服制剂及其制备方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20100114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120904

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20121203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121220

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131219

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140414

R150 Certificate of patent or registration of utility model

Ref document number: 5525814

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees